Optimizing Reperfusion to Improve Outcomes and Neurologic Function

ClinicalTrials.gov ID: NCT06990867

Public ClinicalTrials.gov record NCT06990867. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of JX10 in Acute Ischemic Stroke With Late Presentations

Study identification

NCT ID: NCT06990867
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Corxel Pharmaceuticals; Industry
Enrollment: 740 participants

Conditions and interventions

Conditions

Acute Ischemic Stroke

Interventions

JX10 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 90 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 14, 2025
Primary completion: Oct 30, 2029
Completion: Dec 30, 2029
Last update posted: Mar 12, 2026

2025 – 2029

United States locations

U.S. sites: 17
U.S. states: 13
U.S. cities: 17

Facility	City	State	ZIP	Site status
Corxel Investigational Site	Long Beach	California	90806	Recruiting
Corxel Investigational Site	Sacramento	California	95817	Recruiting
Corxel Investigational Site	Colorado Springs	Colorado	80909	Recruiting
Corxel Investigational Site	Washington D.C.	District of Columbia	20007	Recruiting
Corxel Investigational Site	Delray Beach	Florida	33484	Recruiting
Corxel Investigational Site	Chicago	Illinois	60616	Recruiting
Corxel Investigational Site	Wichita	Kansas	67214	Recruiting
Corxel Investigational Site	Baltimore	Maryland	21215	Recruiting
Corxel Investigational Site	Kalamazoo	Michigan	49048	Recruiting
Corxel Investigational Site	Traverse City	Michigan	49684	Recruiting
Corxel Investigational Site	St Louis	Missouri	63110	Recruiting
Corxel Investigational Site	Great Neck	New York	11021	Recruiting
Corxel Investigational Site	New York	New York	10029	Recruiting
Corxel Investigational Site	Toledo	Ohio	43606	Recruiting
Corxel Investigational Site	Tulsa	Oklahoma	74104	Recruiting
Corxel Investigational Site	Dallas	Texas	75246	Recruiting
Corxel Investigational Site	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06990867, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 12, 2026 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06990867 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →